Why people use Tirzepatide for Type 2 diabetes
Your A1C is creeping up. Mounjaro / Tirzepatide for diabetes? The honest answer: yes, and it clears the highest bar - it is FDA-approved for this. SURPASS trials showed superior A1C reduction vs other GLP-1s.
This page covers what's known, what's not, and what the editorial take is for normal humans considering Tirzepatide for Type 2 diabetes.
What the evidence says
Evidence tier: FDA-approved. FDA-approved with multiple randomized trials behind it. The strongest evidence tier in this matrix.
- SURPASS trials showed superior A1C reduction vs other GLP-1s.
- Average A1C drop of 2-2.5 percentage points at full dose.
- FDA-approved for adult Type 2 diabetes.
Protocol notes
Standard titration. Often added to metformin or as monotherapy depending on baseline.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full Tirzepatide directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch